Jack Cuzick is a director of Wolfson Institute of Preventive Medicine in London. He is also head of Centre for Cancer Prevention and John Snow Professor of Epidemiology at Queen Mary, University of London. He holds a PhD in Mathematics and has previously worked at Oxford University and Columbia University, New York. His current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening. He is currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. He has worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role and also has demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness. He is also involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer. He is the statistician for several major breast cancer trials and maintains an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials. He is a Fellow of the Royal Society, the Academy of Medical Sciences, the Royal Statistical Society, the Institute of Mathematical Statistics and an Honorary Fellow of the Royal College of Physicians. In 2007 and subsequently, he was chosen by Thompson Scientific as one of the twelve hottest researchers in all of science. He was awarded the AACR Cancer Prevention Prize in 2012, the CRUK Translational Cancer Research Prize team prize in 2014, Robert Sutherland Award for Excellence in Translational Research (Australia) and the ACS Medal of Honor in 2015. He is the author of more than 550 peer-reviewed papers and has published in all the major medical journals.